Moderna Inc (MRNA)
Return on total capital
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | -3,583,000 | -3,904,000 | 9,420,000 | 13,296,000 | -763,144 |
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 10,901,000 | 13,854,000 | 19,123,000 | 14,145,000 | 2,561,000 |
| Return on total capital | -32.87% | -28.18% | 49.26% | 94.00% | -29.80% |
December 31, 2024 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $-3,583,000K ÷ ($—K + $10,901,000K)
= -32.87%
To analyze Moderna Inc's return on total capital over the years, we can observe significant fluctuations.
- For the fiscal year ending December 31, 2020, the return on total capital was reported at -29.80%. This negative value suggests that the company utilized more capital than it generated in returns, indicating inefficiency in capital allocation.
- However, there was a substantial improvement in performance by the end of December 31, 2021, with a return on total capital of 94.00%. This significant positive return indicates that Moderna Inc was able to generate considerable returns in relation to the total capital employed, signaling a more efficient use of resources.
- Moving to December 31, 2022, the return on total capital decreased to 49.26%, still reflecting a strong performance in generating returns relative to capital invested, albeit at a lower rate than the previous year.
- The following year, December 31, 2023, saw a decline in return on total capital to -28.18%. This negative return implies that Moderna Inc may have experienced challenges in generating returns with the capital employed, potentially indicating inefficiencies or declining performance.
- Lastly, for the fiscal year ending December 31, 2024, the return on total capital decreased further to -32.87%. This negative trend suggests continued difficulties in achieving positive returns in relation to the capital invested.
In conclusion, while Moderna Inc demonstrated periods of strong performance in generating returns relative to total capital, there were also years of negative returns. These fluctuations may indicate varying levels of efficiency in capital utilization and overall financial performance over the analyzed period.
Peer comparison
Dec 31, 2024